## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934 (Amendment No. ) Filed by a party other than the Registrant  $\ \Box$ 

Filed by the Registrant $oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant Filed by a party other than the Registrant oxin Signature Filed by a party other than the Registrant Filed by a party other Filed by a party other Filed by a party other Fil$			
Check the appropriate box:			
□ Prelim		minary Proxy Statement	
	Definitive Proxy Statement Definitive Additional Materials		
		iting Material under §240.14a-12	
	Officialing infaction under 32-70.1-40-12		
ROCKET PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter)			
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)			
Payment of Filing Fee (Check the appropriate box):			
$\times$	☑ No fee required.		
Ш	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.		
	(1)	Title of each class of securities to which transaction applies:	
	(2)	A second to such as of a social as a bight to such as a solice.	
	(2)	Aggregate number of securities to which transaction applies:	
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	(4)	Proposed maximum aggregate value of transaction:	
	(5)	Total fee paid:	
	☐ Fee paid previously with preliminary materials.		
		Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.	
	(1)	Amount Previously Paid:	
	(2)	Form, Schedule or Registration Statement No.:	
	(3)	Filing Party:	
	(4)	Date Filed:	

## \*\*\* Exercise Your *Right* to Vote \*\*\*

## Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 16, 2020.

### **ROCKET PHARMACEUTICALS, INC.**

## **Meeting Information**

**Meeting Type:** Annual Meeting For holders as of: April 20, 2020

**Date:** June 16, 2020 Time: 9:00 a.m., Eastern Time

Location: Meeting live via the Internet-please visit www.virtualshareholdermeeting.com/RCKT2020.

The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit www.virtualshareholdermeeting.com/RCKT2020 and be sure to have the information that is printed in the box marked by the arrow → XXXX XXXX XXXX XXXX (located on the following page).

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

ROCKET PHARMACEUTICALS, INC. 350 FIFTH AVE SUITE 7530 NEW YORK, NY 10118

## Before You Vote -

How to Access the Proxy Materials

#### Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT FORM 10-K

#### **How to View Online:**

#### How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639

3) BY E-MAIL\*: sendmaterial@proxyvote.com

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 2, 2020 to facilitate timely delivery.

## — How To Vote —

Please Choose One of the Following Voting Methods

#### **Vote By Internet:**

Before The Meeting:

Go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow → XXXX XXXX XXXX XXXX (located on the following page) available and follow the instructions.

During The Meeting:

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

### **Voting Items**

## The Board of Directors recommends you vote <u>FOR ALL</u> the following directors:

1. Election of Directors

#### Nominees:

- 1a. Roderick Wong
- 1b. Carsten Boess
- 1c. Pedro Granadillo
- 1d. Gotham Makker
- 1e. Gaurav Shah
- 1f. David P. Southwell
- 1g. Naveen Yalamanchi
- 1h. Elisabeth Björk

## The Board of Directors recommends you vote <u>FOR</u> proposal 2:

2. Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.

# The Board of Directors recommends you vote <u>AGAINST</u> proposal 3:

3. Stockholder proposal to amend the Company's articles of incorporation and/or by-laws to provide that directors shall be elected by the affirmative vote of the majority of votes cast at an annual meeting of stockholders in uncontested elections.

**NOTE:** To transact such other business as may properly come before the meeting or any adjournment thereof.